Coronary Arterial Disease (CAD)NCT07825376
Branching Scenario-Based Education in Coronary Artery Disease
A study testing Virtual Reality-Based Branching Scenario Education and Tablet-Based Branching Scenario Education in people with Coronary Arterial Disease (CAD), run by Abant Izzet Baysal University at 1 site in Turkey (Türkiye).
Trial summary
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Coronary Arterial Disease (CAD)
- What is being tested?
- Virtual Reality-Based Branching Scenario Education and Tablet-Based Branching Scenario Education
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2026to Apr 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged 18-65 years.
- Diagnosed with coronary artery disease.
- Newly initiated on antiplatelet therapy.
- Conscious and able to communicate.
- Physically and cognitively able to use a virtual reality headset.
- Able to read, write, and understand Turkish.
Show all 10Show fewer
- Willing to provide written informed consent.
- Willing to participate in the education and follow-up process.
- Has not previously received education about coronary artery disease.
- Able to use a smartphone.
Who cannot join
- Cognitive impairment or mental illness preventing communication.
- Visual or hearing impairment preventing participation in the virtual reality education.
- Participation in another clinical study at the same time.
- Diagnosis of malignant disease.
- Bleeding disorder or active bleeding risk.
- Hospitalization within the previous 3 months due to acute myocardial infarction, stroke, or another serious cardiovascular event.
- Unable to understand the educational materials.
- Refusal to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: The Effect of Branching Scenario-Based Education Delivered Through Virtual Reality and Tablet on Cardiovascular Disease Risk Awareness and Antiplatelet Medication Adherence in Patients With Coronary Artery Disease: A Randomized Controlled Trial
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.
- Conditions
- Coronary Arterial Disease (CAD)
- Being tested
- Virtual Reality-Based Branching Scenario Education, Tablet-Based Branching Scenario Education
- Keywords
- coronary artery disease, virtual reality, treatment adherence
- Medical subject headings
- Coronary Artery Disease, Treatment Adherence and Compliance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Reality-Based Branching Scenario EducationBehavioural
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
Tablet-Based Branching Scenario EducationBehavioural
Participants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment.
| Study group | Role | What they receive |
|---|---|---|
| control group | No intervention | participants in the control group receive routine clinical education. |
| virtual reality education | Experimental | Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a virtual reality headset. Receives: Behavioral: Virtual Reality-Based Branching Scenario Education |
| Tablet Education | Experimental | Participants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a tablet and headphones. Receives: Behavioral: Tablet-Based Branching Scenario Education |
What is being measured
The primary outcome is the main question the study is designed to answer.
cardiovascular disease risk awareness assessment scale score
Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.
Measured: baseline and immediately after the educational intervention
medication adherence report scale score
Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.
Measured: Baseline, immediately after the intervention, and 3 months follow-up
Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire
Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.
Measured: Baseline, immediately after the intervention, and 3 months after the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Arterial Disease (CAD)Studies of the same condition, open and under way.
- More trials run by Abant Izzet Baysal UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abant Izzet Baysal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Saadet Can Çiçek, Abant Izzet Baysal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07825376
- Sponsor's protocol ID
- BAIBU-SBF-SOY-2026
- Status last verified
- Sep 2026
- First submitted
- 18 Aug 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: for the protection of personal data
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Branching Scenario-Based Education Delivered Through Virtual Reality and Tablet on Cardiovascular Disease Risk Awareness and Antiplatelet Medication Adherence in Patients With Coronary Artery Disease: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07825376
- Acronym / sponsor ID
- BAIBU-SBF-SOY-2026
- Conditions
- Coronary Arterial Disease (CAD)
- Keywords
- coronary artery disease, virtual reality, treatment adherence
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Abant Izzet Baysal UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 17 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial aims to evaluate the effects of nurse-led branching scenario-based education delivered through virtual reality and tablet on cardiovascular disease risk awareness and adherence to antiplatelet medication in patients with coronary artery disease. Participants will be randomly assigned to a virtual reality education group, a tablet-based education group, or a control group receiving routine hospital education. Cardiovascular disease risk awareness and medication adherence will be assessed before and after the educational intervention and during follow-up.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| control group | No intervention | –participants in the control group receive routine clinical education. |
| virtual reality education | Experimental | Behavioral: Virtual Reality-Based Branching Scenario EducationParticipants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a virtual reality headset. |
| Tablet Education | Experimental | Behavioral: Tablet-Based Branching Scenario EducationParticipants in this arm will receive nurse-led branching scenario-based education on cardiovascular disease risk factors and medication adherence using a tablet and headphones. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Aged 18-65 years.
- Diagnosed with coronary artery disease.
- Newly initiated on antiplatelet therapy.
- Conscious and able to communicate.
- Physically and cognitively able to use a virtual reality headset.
Key exclusion criteria (8 listed)
- Cognitive impairment or mental illness preventing communication.
- Visual or hearing impairment preventing participation in the virtual reality education.
- Participation in another clinical study at the same time.
- Diagnosis of malignant disease.
- Bleeding disorder or active bleeding risk.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Reality-Based Branching Scenario EducationParticipants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a virtual reality (VR) headset. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment. | Behavioural | virtual reality education |
| Tablet-Based Branching Scenario EducationParticipants will first complete a pre-test assessment. They will then receive nurse-led coronary artery disease education through an interactive, branching scenario-based educational program delivered using a tablet. The educational content includes visual, interactive, and scenario-based learning activities, with different learning pathways and feedback based on participants' choices. Following the educational intervention, participants will complete a post-test assessment. | Behavioural | Tablet Education |
Primary outcome
cardiovascular disease risk awareness assessment scale score
Time frame: baseline and immediately after the educational intervention
Change in cardiovascular disease risk awareness, assessed using the Turkish validated 22-item Cardiovascular Disease Risk Awareness Assessment Scale (CVD-RAAS). The knowledge domain score ranges from 0 to 8, with higher scores indicating higher knowledge about myocardial infarction and stroke. The total score for the 14-item Likert-type awareness subscales ranges from 14 to 56, with higher scores indicating greater awareness of cardiovascular disease risks, healthier dietary intentions, and higher readiness for behavioral change.
medication adherence report scale score
Time frame: Baseline, immediately after the intervention, and 3 months follow-up
Change in medication adherence, assessed using the Turkish validated 5-item Medication Adherence Report Scale (MARS-5). Each item is scored on a 5-point Likert scale (1 = always to 5 = never). Total scores range from 5 to 25, with higher scores indicating greater medication adherence.
Cardiovascular Disease Risk Awareness Assessed by the Cardiovascular Disease Risk Awareness Assessment Questionnaire
Time frame: Baseline, immediately after the intervention, and 3 months after the intervention.
Cardiovascular disease risk awareness will be assessed using the Turkish version of the Cardiovascular Disease Risk Awareness Assessment Questionnaire (CDRAAQ), a 22-item instrument consisting of an 8-item knowledge section and three subscales: perceived risk of heart attack/stroke, healthy eating intentions, and perceived benefits and intentions to change. The knowledge items are scored as correct or incorrect, with each correct response receiving 1 point. The subscale items are rated on a 4-point Likert scale from 1 (strongly disagree) to 4 (strongly agree), with reverse scoring applied where appropriate. Higher scores indicate greater cardiovascular disease risk awareness, greater knowledge of heart attack and stroke, and greater readiness for health-related behavioral change.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
- Individual participant dataSharing planned: No. for the protection of personal data
Related trials for Coronary Arterial Disease (CAD)
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Not yet recruitingObservational study
Preoperative Gastric Ultrasound and Anaesthetic Management in Patients Undergoing Coronary Artery Bypass Grafting
Preoperative Fasting, Pulmonary Aspiration During Anesthetic Induction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Reality-Based Branching Scenario Education and Tablet-Based Branching Scenario Education in people with Coronary Arterial Disease (CAD), run by Abant Izzet Baysal University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Saadet Can Çiçek, PhD (+905062846936, saadet.cancicek@ibu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
cardiovascular disease risk awareness assessment scale score (time frame: baseline and immediately after the educational intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.